FDA OKs automatic generic swap for brand-name insulin, a move that will lower costs

The move will allow pharmacists to automatically substitute the cheaper version, just as they do with generic pills for other kinds of drugs.

SHARE FDA OKs automatic generic swap for brand-name insulin, a move that will lower costs
Till now, doctors have needed to specifically prescribe what’s called a biosimilar or OK substituting it for a more expensive brand-name insulin. No longer.

Till now, doctors have needed to specifically prescribe what’s called a biosimilar or OK substituting it for a more expensive brand-name insulin. No longer. The FDA’s move could save diabetics and health plans millions of dollars a year

AP

Federal regulators have taken a step that will make it easier to get a cheaper, near-copy of a brand-name insulin at the drugstore.

Till now, doctors have needed to specifically prescribe what’s called a biosimilar or approve substituting it for a more expensive brand-name insulin.

Now, a move by the federal Food and Drug Administration will allow pharmacists to automatically substitute the cheaper version, just as they do with generic pills for other kinds of drugs.

It’s the FDA’s first approval of an “interchangeable” biosimilar — a near-copy of an injected biologic medicine that’s manufactured inside living cells. It could save diabetics and health plans millions of dollars a year and encourage other drugmakers to create more biosimilar medicines.

Health data firm IQVIA projects U.S. savings from increasing use of biosimilars from 2020 through 2024 will top $100 billion.

The FDA agreed that Viatris Inc.’s Semglee was interchangeable with widely used Lantus, a long-acting insulin.

Depending on the pharmacy, Semglee injector pens cost about $150 to $190 without insurance for a typical month’s supply, compared to $340 to $520 for the same supply of brand-name Lantus.

Approval of a second such interchangeable biosimilar of a fast-acting insulin appears imminent from the same developers, Generic giant Viatris, based in Pittsburgh, and its partner Biocon, based in India.

Mylan N.V., one of two companies that merged to create Viatris last December, launched Semglee in the United States last summer.

Red tape, lengthy patents and pushback from brand-name drugmakers have limited U.S. sales of biosimilars to far below levels in Europe.

“These products are highly similar but much more affordable,” said Sean McGowan, head of biosimilars for the drug wholesaler AmerisourceBergen.

Only 20 of 29 FDA-approved biosimilars — for cancer and immune disorders like rheumatoid arthritis — are sold in the United States so far, he said.

The Latest
This is a deeply beautiful piece of writing, bleakly funny, poetic in its plainness, aching in its intense empathy for the characters, brought to life by Laurie Metcalf and Micah Stock at Steppenwolf Theatre.
The list is a combination of obscure players on the recruiting front who raised their stock and others who have received attention — and even offers — but should have a whole lot more.
The Bears are rising, but they aren’t the only ones. There are still plenty of hurdles in their path to contending.
A self-described hippie, Ms. Lurie moved to Chicago in 1973 to work as an intensive care nurse. She wound up giving tens of millions of dollars to Northwestern University, Ann & Robert H. Lurie Children’s Hospital of Chicago, Greater Chicago Food Depository, PAWS Chicago and several other organizations both in the city and beyond.
Chicago’s food scene is “the lifeblood” of “The Bear,” cast member Ebon Moss-Bachrach told reporters during a press conference call with co-stars Jeremy Allen White and Ayo Edebiri on Monday.